# Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy

> **NCT05665348** · PHASE2,PHASE3 · COMPLETED · sponsor: **Federation Francophone de Cancerologie Digestive** · enrollment: 229 (actual)

## Conditions studied

- HCC - Hepatocellular Carcinoma
- Metastatic Cancer
- Metastatic Tumor

## Interventions

- **DRUG:** Ipilimumab Injection
- **DRUG:** Atezolizumab Injection
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT05665348
- **Lead sponsor:** Federation Francophone de Cancerologie Digestive
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-09
- **Primary completion:** 2025-05-12
- **Final completion:** 2025-05-12
- **Target enrollment:** 229 (ACTUAL)
- **Last updated:** 2026-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05665348

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05665348, "Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05665348. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*